SCHEMBL418157

SCHEMBL418157

COC(=O)c1cc(Cl)ccc1NC(=O)C=Cc1ccc(-c2ccccc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
HPGD P15428 6/20 0.59
KDM4E B2RXH2 5/20 0.59
LTB4R Q15722 4/20 0.59
TRPM2 O94759 4/20 0.59
EGFR P00533 1/20 0.59
TRPA1 O75762 2/20 0.58
MAPT P10636 2/20 0.57
RAB9A P51151 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
MEN1 O00255 3/20 0.54
NPC1 O15118 3/20 0.54
KMT2A Q03164 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
TP53 P04637 1/20 0.54
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
GLA P06280 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL418156 1.00 ALDH1A1 (0.59) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL420830 0.91 EGFR (0.57) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL420831 0.91 EGFR (0.57) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL420926 0.88 TRPM2 (0.74) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL420925 0.88 TRPM2 (0.74) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL6786949 0.83 TRPA1 (0.74) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL6786952 0.83 TRPA1 (0.74) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL4833514 0.83 LTB4R (0.60) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL4833530 0.83 LTB4R (0.60) ALDH1A1HPGDKDM4ELTB4RTRPM2
SCHEMBL418392 0.81 MAOB (0.53) ALDH1A1HPGDKDM4EEGFRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 ALDH1A1 1450/4885HPGD 904/4885KDM4E 4490/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 ALDH1A1 1450/4885HPGD 904/4885KDM4E 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.